
Inpefa to be added on pharmacy benefit manager’s basic and high-performance formularies for commercially insured patients.

Inpefa to be added on pharmacy benefit manager’s basic and high-performance formularies for commercially insured patients.

Webcasts
Webinar Date/Time: Tue, Nov 28, 2023 10:00 AM EST | 9:00 AM CT | 3:00 PM GMT | 4:00 PM CET

Webcasts
Webinar Date/Time: Tue, Nov 14, 2023 10:00 AM EST | 9:00 AM CT | 3:00 PM GMT | 4:00 PM CET

A look at the intersection of rigorous compliance and ethical behavior: independent, charitable patient assistance foundations.

George Hampton, president and CEO, Currax Pharmaceuticals, discusses the obesity treatment landscape, payment options available to insured and uninsured patients, and how pharma can make obesity treatments more affordable in an exclusive Q&A with Pharm Exec.

Webcasts
Webinar Date/Time: Tuesday, September 19th, 2023 at 8am PDT | 11am EDT | 4pm BST

In this exclusive Q&A, Vishali Amin, chief of staff to the office of the president and senior director of customer success for Kalderos, discusses the biggest hurdles to drug affordability, how patients can become aware of drug discounts, how drugs are selected for regulatory discount programs, and drug pricing strategies.

In this exclusive Q&A, Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, shares her perspective on the biggest drug pricing challenges today, current efforts to lower drug pricing, and the Inflation Reduction Act.

Frederique Welgryn, global vice president for women's health, Perrigo, shares insight into the approval of Opill (norgestrel), a progestin-only contraception, in this exclusive Q&A.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.

Webcasts
Webinar Date/Time: Tue, Aug 29, 2023 10:00 AM EDT

Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically clinical trials.

Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.

Rose Blackburne, MD, MBA, vice president, global head, general medicine, PPD Clinical Research, Thermo Fisher Scientific, discusses health equity in pharma, specifically racial biases, and how the industry can address inequities in access and care going forward.

The Medicare Part D cap won’t solve need for financial assistance.

New federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.

Stefan Merlo, Vice President, Commercial Development, CSL Seqirus discusses how COVID-19 has evolved the discussion of vaccines and the long-term concerns stemming from flu vaccine fatigue.

BCG’s 2022 benchmark study uncovers new competencies needed for pharma access leaders in enterprise-wide business strategy, where thoughtfully designed approaches and goals focused on shared priority and responsibility are increasingly important.

Experts explore MA's evolving role and skill set in engaging effectively with clinicians and other external stakeholders.

German laws, European VBCs, and trends in China, Brazil, and Saudi Arabia are changing the way global market access works.

Webcasts
Webinar Date/Time: Tue, May 16, 2023 2:00 PM EDT

Shift focus in orphan and ultra-orphan messaging to clinical benefit.

Sunil Verma, SVP, Global Head of Oncology, Medical, AstraZeneca discusses how the Medical Affairs role will become more strategic and effective with data.

Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes that impact Medicare, as well as the Foundation's near-term goals.

Biopharma companies can foster patient-centered innovation by focusing on unmet needs along each stage of the patient journey while collaborating with key stakeholders directly or indirectly responsible for disease management.